Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid, Remifentanil, and Hydralazine and bleeding volume in dacryocystitis surgery
IRCT20210614051574N10Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tranexamic acid, remifentanil and hydralazine in dacryocystitis, sponsored by Isfahan University of Medical Sciences. Primary endpoint: Intraoperative bleeding volume. Started Jul 2019; status: completed.
02
Drugs
tranexamic acidremifentanilhydralazine
03
Conditions
dacryocystitis
Beyond the preview
Go deeper on IRCT20210614051574N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210614051574N10.